NFKB1 and cancer: Previous studies in our laboratory demonstrate that 5-fluorouracil (5-FU)- and gemcitabine (dFdC)-resistant cancer cell lines possess higher NFκB activity (Wang and Cassidy, 2003; Guo et al, 2009).